Coinfection with HIV and hepatitis C virus (HCV) is a common occurrence, with approximately 25% of HIV-infected patients in the United States being HCV-positive as well. According to the Centers for Disease Control and Prevention (CDC), HIV-HCV coinfection significantly increases patient risk for developing liver disease, often leading to liver-related death in coinfected individuals. A group based in France recently presented research they hope can lead to the eradication of HIV-HCV coinfection, potentially paving the way to rid the world of HCV in HIV-positive patients. At the 2017 Conference on Retroviruses and Opportunistic infections (CROI),
At the 2017 Conference on Retroviruses and Opportunistic infections (CROI), lead investigator, Victor Virlogeux, MD, from the Institut national de la santé et de la recherche médicale (INSERM), presented his group’s research on the eradication of HIV-HCV coinfection within the next decade. Dr. Virlogeux’s group utilized mathematical modeling to make projections on the impact direct-acting antiviral drugs (DAAs) will have on HIV-HCV infections over the next 10 years. The study utilized data, including
The study utilized data, including incidence of infection and treatment information, from the DatAIDS cohort, a collaborative effort between 15 HIV treatment centers in France. The authors examined multiple risk groups including: high-risk men who have sex with men (MSM), low-risk MSM, female and male heterosexuals, intravenous drug users (IVDU), as well as patients in additional risk categories. The researchers also examined the undiagnosed HIV-HCV coinfected population by utilizing a previously published model. Using this information, the authors examined the effect of increasing DAA coverage on HCV incidence and prevalence in the different risk groups.
Hepatitis C virus seropositivity was associated with an increased risk for osteoporosis and kidney disease in patients with HIV, but infection was not associated with other nonliver related conditions, according to researchers in Switzerland.
“With the advent of direct-acting antivirals offering high cure rates within 12-24 weeks, the landscape of HCV treatment has changed dramatically. … Many studies evaluated the association between HCV seropositivity and nonliver related diseases,” Helen Kovari, MD, of the division of infectious diseases and hospital epidemiology at University Hospital Zurich, and colleagues wrote. “In order to assess the role of ongoing viral replication independent of behavior and social characteristics associated with HCV exposure, it is important to investigate the contribution of HCV viremia on extrahepatic morbidity and mortality.”
Kovari and colleagues enrolled patients who had participated in the Swiss HIV Cohort Study, an ongoing prospective cohort study that has observed HIV–infected adults since 1988. They compared 2,503 HCV seropositive patients with an equal number of seronegative patients, as well as comparing HCV–viremic and nonviremic patients.